Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.

ABSTRACT:

Objective

To assess the efficacy, safety, and tolerability of adjunctive brivaracetam (BRV), a selective, high-affinity ligand for SV2A, for treatment of partial-onset (focal) seizures (POS) in adults.

Methods

Data were pooled from patients (aged 16-80 years) with POS uncontrolled by 1 to 2 antiepileptic drugs receiving BRV 50, 100, or 200 mg/d or placebo, without titration, in 3 phase III studies of BRV (NCT00490035, NCT00464269, and NCT01261325, ClinicalTrials.gov, funded by UCB Pharma). The studies had an 8-week baseline and a 12-week treatment period. Patients receiving concomitant levetiracetam were excluded from the efficacy pool.

Results

In the efficacy population (n = 1,160), reduction over placebo (95% confidence interval) in baseline-adjusted POS frequency/2

SUBMITTER: Ben-Menachem E 

PROVIDER: S-EPMC4955277 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature